Boston Scientific misses 2026 guidance after cyberattack

Boston Scientific misses 2026 guidance after cyberattack

Tue, September 8, 2026 at 8:40 PM GMT+3 2 min read

• BSX -4.63%

Boston Scientific warned Tuesday that it is unlikely to meet its full-year and third-quarter net sales growth and adjusted earnings per share guidance, after a cyberattack disrupted manufacturing and order fulfillment across its global operations. Boston Scientific stock fell more than 4% to $45.73 on Tuesday.

In a regulatory filing Tuesday, the company said unauthorized activity on its IT systems, which it first detected on August 25, triggered a network outage that left employees unable to reach operating systems and business applications. At the end of July, Boston Scientific had projected full-year adjusted earnings of $3.28 to $3.32 per share and full-year net sales growth of 5.5% to 6.5%. For the third quarter, it had forecast adjusted earnings of 80 cents to 82 cents per share and net sales growth of 3% to 5%.

The company said it anticipates clawing back some of the revenue lost during the disruption, though it cautioned that the total financial toll has yet to be determined. The company will share a revised operational and financial picture, factoring in the cyberattack's consequences, alongside its third-quarter earnings release on October 28. Boston Scientific added that its long-term financial condition is not expected to suffer a material impact from the attack.

Recovery is underway but not complete. The company said its logistics infrastructure is largely back online, with key distribution hubs handling product volumes that meet or exceed their typical throughput. Sterilization facilities are operational, and manufacturing has resumed at most of its global facilities. The company said it has not identified evidence of ongoing unauthorized access to its systems, though the investigation remains ongoing.

Boston Scientific's situation is drawing comparisons to a March attack on rival Stryker, which also disrupted manufacturing, ordering, and shipping, according to MedTech Dive. J.P. Morgan analysts flagged two structural disadvantages for Boston Scientific: its portfolio is weighted toward single-use consumables rather than big-ticket capital goods, so procedures that go unserved during the outage are largely unrecoverable sales, and with only four months remaining in the calendar year the company has far less runway to make up ground than Stryker did after its spring attack.

Tuesday's warning compounds an already difficult year for the Marlborough, Massachusetts-based company. Boston Scientific reduced its full-year profit and sales growth outlook in late July after its Watchman heart implant underperformed, hurt by a shift in clinical practice toward bundling the device with other procedures during a single patient visit. The company had already cut its forecast once earlier in the year before that July reduction. Boston Scientific stock has fallen roughly 50% this year.